论文部分内容阅读
目的探讨雌激素加安宫黄体酮行激素治疗(HT)对子宫肌瘤的影响。方法选取2002-01-2003-01在上海交通大学附属第一人民医院门诊就诊的绝经1年以上的子宫肌瘤患者45例,采用倍美力0.625mg配伍安宫黄体酮2mg每天各1片,在治疗前及治疗后3个月、6个月及12个月分别检测子宫肌瘤大小及子宫内膜厚度的变化及雌激素(E2)和卵泡刺激素(FSH)的变化。结果HT治疗3个月后子宫肌瘤体积由治疗前(26.9±12.3)mm3增大到(33.5±14.5)mm3,治疗6个月及12个月时分别为(33.1±10.2)mm3和(34.8±11.7)mm3,均较治疗前增大,差异有统计学意义(P<0.01),但治疗3个月后继续治疗子宫肌瘤无明显增大。结论倍美力配伍安宫黄体酮行激素治疗3个月以上、12个月以内对子宫肌瘤肌瘤大小无明显影响。
Objective To investigate the effect of hormones estrogen plus medroxyprogesterone (HT) on uterine fibroids. Methods From January 2002 to January 2003, 45 patients with uterine fibroids over 1 year in the First People's Hospital Affiliated to Shanghai Jiaotong University were enrolled. The patients were treated with Beomei 0.625mg, The changes of uterine leiomyoma size and endometrial thickness and the changes of estrogen (E2) and follicle stimulating hormone (FSH) were detected before treatment, 3 months, 6 months and 12 months after treatment. Results The volume of uterine myoma increased from (26.9 ± 12.3) mm3 to (33.5 ± 14.5) mm3 after 3 months of HT treatment and was 33.1 ± 10.2 mm3 and 34.8 mm after 6 months and 12 months respectively ± 11.7) mm3, respectively, compared with before treatment, the difference was statistically significant (P <0.01), but no significant increase in the treatment of uterine fibroids after 3 months of treatment. Conclusion BeiMeiLi progesterone and progesterone hormone hormone therapy for more than 3 months, 12 months within the fibroid fibroids size no significant effect.